|Bid||0.00 x 1100|
|Ask||0.00 x 1800|
|Day's Range||49.96 - 50.05|
|52 Week Range||25.10 - 57.19|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||52.75|
Fledgling biotechs and medical-technology startups in the U.S. and Europe have found a new source of funding for their costly research: China. Foreign health-care investments by Chinese venture-capital and private-equity firms reached a record $3.5 billion last year, up from $500 million four years earlier, according to Bain & Co. Much of the new money has gone to buying stakes in U.S. and European firms. All nine named investors in a $300 million financing round last month for Grail Inc, a blood-testing startup based in Menlo Park, Calif., were from Hong Kong or mainland China.
Biotechnology startups are riding a renewed wave of investor confidence in their industry to make the leap to the public markets. Initial public offerings in the sector are in recovery mode after falling off in 2016, when the number of offerings from venture-backed drugmakers dropped to 19 from 35 in 2015, according to market tracker Dow Jones VentureSource. Last year, biotech IPOs climbed to 25.
NEW YORK , June 5, 2018 /PRNewswire/ -- ARMO BioSciences, Inc. (ARMO) Lifshitz & Miller announces investigation into possible breaches of fiduciary duties in connection with the proposed sale of ARMO ...
NEW YORK, NY / ACCESSWIRE / June 4, 2018 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...
NEW YORK , May 18, 2018 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...
BALA CYNWYD, PA / ACCESSWIRE / May 16, 2018 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of ARMO Biosciences, Inc. ("ARMO" ...
The high-profile departure would be the latest in a string of exits of top investors in recent years from one of Silicon Valley's oldest and most successful venture firms.
WeissLaw is investigating whether ARMO's Board acted to maximize shareholder value prior to entering into the agreement. Notably, at least one analyst set a target price of $75.00 per share, or $25.00 above the offer price. Moreover, the deal is a strategic transaction that will expand LLY's drug portfolio and provide LLY a foothold in the very lucrative cancer immunotherapy industry.
Take one part great earnings and one part tremendous skepticism, add in low inflation and you end up with this astonishing stealth rally. Jim Cramer explains it.
BALA CYNWYD, PA / ACCESSWIRE / May 10, 2018 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of ARMO Biosciences, Inc. ("ARMO'' ...
The latest earnings release ARMO BioSciences Inc’s (NASDAQ:ARMO) announced in December 2017 indicated company earnings became less negative compared to the previous year’s level – great news for investors BelowRead More...
Legendary venture capital firm Kleiner Perkins Caufield & Byers bought into Redwood City's ARMO BioSciences Inc. in December 2012 when Series A shares sold for $1. It stuck with the company into a January IPO at $17 and now with a $50-per-share buyout by Eli Lilly & Co.
Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of ARMO BioSciences, Inc. stockholders concerning the proposed acquisition of the company by Eli Lilly and Company .
The deal between the two companies will have Eli Lilly acquiring ARMO Biosciences Inc for $50 per share. This represents a roughly 68% premium to ARMO stock’s closing price on Wednesday. The agreement between ARMO Biosciences Inc and Eli Lilly will have the latter making a tender offer of $50 per share for ARMO stock.
NEW YORK , May 10, 2018 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against ARMO BioSciences, Inc. (NASDAQ: ARMO) and its board of directors for breach of fiduciary duty concerning ...
Pharma giant Eli Lilly and Co. will buy small cancer immunotherapy drug developer ARMO BioSciences Inc., a Redwood City company that went public in January, in a $1.6 billion all-cash deal.
Lilly's offer of $50 per share in cash represents a premium of 68 percent to Armo's Wednesday close. Armo's shares were trading close to the offer price at $49.73, while Lilly's shares rose 1.2 percent to $80.22. The deal comes just four months after Armo went public and would give Lilly access to the smaller drug developer's lead candidate, pegilodecakin.
The following statement is being issued by Levi & Korsinsky, LLP:
SAN DIEGO , May 10, 2018 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of ARMO BioSciences, Inc. (NASDAQ: ARMO) breached their ...
INDIANAPOLIS and REDWOOD CITY, Calif., May 10, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) and ARMO BioSciences, Inc. (ARMO) today announced a definitive agreement for Lilly to acquire ARMO for $50 per share, or approximately $1.6 billion, in an all-cash transaction. ARMO BioSciences is a late-stage immuno-oncology company that is developing a pipeline of novel, proprietary product candidates designed to activate the immune system of cancer patients to recognize and eradicate tumors.
REDWOOD CITY, Calif., April 25, 2018-- ARMO BioSciences, Inc., a late-stage immuno-oncology company, today announced three abstracts on pegilodecakin, a long-acting PEGylated form of recombinant human ...
NEW YORK, April 18, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
The number of VC-backed businesses from the region that either went public or were sold dropped to 62 in this year's Q1, compared to 65 in the comparable quarter last year. Here's a look at what happened and nine exits that topped $100 million in value.